These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 8642873)

  • 21. The antiviral action of interferon is potentiated by removal of the conserved IRTAM domain of the IFNAR1 chain of the interferon alpha/beta receptor: effects on JAK-STAT activation and receptor down-regulation.
    Basu L; Yang CH; Murti A; Garcia JV; Croze E; Constantinescu SN; Mullersman JE; Pfeffer LM
    Virology; 1998 Mar; 242(1):14-21. PubMed ID: 9501047
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The amino-terminal region of Tyk2 sustains the level of interferon alpha receptor 1, a component of the interferon alpha/beta receptor.
    Gauzzi MC; Barbieri G; Richter MF; Uzé G; Ling L; Fellous M; Pellegrini S
    Proc Natl Acad Sci U S A; 1997 Oct; 94(22):11839-44. PubMed ID: 9342324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ligand-independent anti-oncogenic activity of the alpha subunit of the type I interferon receptor.
    Colamonici OR; Porterfield B; Domanski P; Handa RK; Flex S; Samuel CE; Pine R; Diaz MO
    J Biol Chem; 1994 Nov; 269(44):27275-9. PubMed ID: 7961637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of the protein tyrosine kinase tyk2 by interferon alpha/beta.
    Barbieri G; Velazquez L; Scrobogna M; Fellous M; Pellegrini S
    Eur J Biochem; 1994 Jul; 223(2):427-35. PubMed ID: 8055912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Double-stranded RNA-dependent protein kinase mediates c-Myc suppression induced by type I interferons.
    Raveh T; Hovanessian AG; Meurs EF; Sonenberg N; Kimchi A
    J Biol Chem; 1996 Oct; 271(41):25479-84. PubMed ID: 8810318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tyk2 plays a restricted role in IFN alpha signaling, although it is required for IL-12-mediated T cell function.
    Shimoda K; Kato K; Aoki K; Matsuda T; Miyamoto A; Shibamori M; Yamashita M; Numata A; Takase K; Kobayashi S; Shibata S; Asano Y; Gondo H; Sekiguchi K; Nakayama K; Nakayama T; Okamura T; Okamura S; Niho Y; Nakayama K
    Immunity; 2000 Oct; 13(4):561-71. PubMed ID: 11070174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity.
    Shaw MH; Boyartchuk V; Wong S; Karaghiosoff M; Ragimbeau J; Pellegrini S; Muller M; Dietrich WF; Yap GS
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11594-9. PubMed ID: 14500783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The receptor interaction region of Tyk2 contains a motif required for its nuclear localization.
    Ragimbeau J; Dondi E; Vasserot A; Romero P; Uzé G; Pellegrini S
    J Biol Chem; 2001 Aug; 276(33):30812-8. PubMed ID: 11399767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A protein tyrosine kinase in the interferon alpha/beta signaling pathway.
    Velazquez L; Fellous M; Stark GR; Pellegrini S
    Cell; 1992 Jul; 70(2):313-22. PubMed ID: 1386289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced Tyk2 gene expression in β-cells due to natural mutation determines susceptibility to virus-induced diabetes.
    Izumi K; Mine K; Inoue Y; Teshima M; Ogawa S; Kai Y; Kurafuji T; Hirakawa K; Miyakawa D; Ikeda H; Inada A; Hara M; Yamada H; Akashi K; Niho Y; Ina K; Kobayashi T; Yoshikai Y; Anzai K; Yamashita T; Minagawa H; Fujimoto S; Kurisaki H; Shimoda K; Katsuta H; Nagafuchi S
    Nat Commun; 2015 Apr; 6():6748. PubMed ID: 25849081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence for nuclear phosphoinositidase C activity in the antiproliferative signals produced by interferon in Burkitt lymphoma cells.
    Cataldi A; Rana R; Bareggi R; Lisio R; Robuffo I; di Valerio V; Miscia S
    Cytokine; 1993 May; 5(3):235-9. PubMed ID: 8218936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
    Leitner NR; Witalisz-Siepracka A; Strobl B; Müller M
    Cytokine; 2017 Jan; 89():209-218. PubMed ID: 26631911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202.
    Yan DH; Wen Y; Spohn B; Choubey D; Gutterman JU; Hung MC
    Oncogene; 1999 Jan; 18(3):807-11. PubMed ID: 9989832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isolation of Daudi cells with reduced sensitivity to interferon. III. Interferon-induced proteins in relation to the phenotype of interferon resistance.
    Dron M; Tovey MG; Eid P
    J Gen Virol; 1985 Apr; 66 ( Pt 4)():787-95. PubMed ID: 2580049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon rapidly induces modifications of chromatin sensitivity to DNase I in Daudi lymphoma cells.
    Cataldi A; Lisio R; Rana R; Bareggi R; Tulipano G; Miscia S
    Exp Cell Res; 1993 Jan; 204(1):167-9. PubMed ID: 7677985
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Insights on the alteration of functionality of a tyrosine kinase 2 variant: a molecular dynamics study.
    Lesgidou N; Eliopoulos E; Goulielmos GN; Vlassi M
    Bioinformatics; 2018 Sep; 34(17):i781-i786. PubMed ID: 30423093
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pillars article: A protein tyrosine kinase in the interferon α/β signaling pathway. Cell. 1992. 70: 313-322.
    Velazquez L; Fellous M; Stark GR; Pellegrini S
    J Immunol; 2011 Dec; 187(11):5479-88. PubMed ID: 22102731
    [No Abstract]   [Full Text] [Related]  

  • 38.
    Prchal-Murphy M; Witalisz-Siepracka A; Bednarik KT; Putz EM; Gotthardt D; Meissl K; Sexl V; Müller M; Strobl B
    Oncoimmunology; 2015 Nov; 4(11):e1047579. PubMed ID: 26451322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunocytochemical detection of phosphatidylinositol 3 kinase in Burkitt lymphoma cells.
    Miscia S; di Baldassarre A; Rana RA; Pucci AM; Cataldi A
    Cell Struct Funct; 1998 Feb; 23(1):17-22. PubMed ID: 9639026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Homozygous Mutation Causing Complete TYK2 Deficiency, with Severe Respiratory Viral Infections, EBV-Driven Lymphoma, and Jamestown Canyon Viral Encephalitis.
    Roussel L; Pham-Huy A; Yu AC; Venkateswaran S; Perez A; Bourdel G; Sun Y; Villavicencio ST; Bernier S; Li Y; Kazimerczak-Brunet M; Alattar R; Déry MA; Shapiro AJ; Penner J; Vinh DC
    J Clin Immunol; 2023 Nov; 43(8):2011-2021. PubMed ID: 37695435
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.